Bristol Myers Squibb signs deal to acquire Orbital Therapeutics for $1.5 billion
NEW YORK: Bristol Myers Squibb (NYSE: BMY, BMS) and Orbital Therapeutics have entered into a definitive agreement in which BMS will acquire Orbital, a privately held biotech firm at the forefront of developing next-generation RNA-based therapies. Orbital’s platform focuses on…